A clinical trial is now underway for a first-in-class immunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma (NHL) or multiple myeloma (MM). The treatment, NKTR-255, which harnesses patients' own natural killer cells to combat these rare but devastating diseases, was developed by Nektar therapeutics, and the trial is being conducted at Cancer Treatment Centers of America (CTCA) in Phoenix, Arizona. Yourway has the resources and expertise to support all clinical trials, whether they are investigating a conventional small molecule drug or next-generation immunotherapies like NKTR-255.